Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review. (14th March 2022)

• Record Type: Journal Article
• Authors: Vincken, Nanette L A; Balak, Deepak M W; Knulst, André C; Welsing, Paco M J; van Laar, Jacob M
• Is Part Of: Rheumatology. Volume 61:Number 11(2022)
• Page Start: 4232
• Page End: 4244
• Publication Date: 2022-03-14
• Subjects: PsA -- glucocorticoids -- psoriasis -- symptom flare-up -- therapeutics -- systematic review; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/keac129
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Objectives: The use of systemic glucocorticoids (SGCs) is traditionally discouraged in the treatment of PsA and psoriasis due to the risk of psoriatic flares. However, despite this recommendation, SGCs are frequently prescribed for these patients. In this study we reappraise the old paradigm that SGCs are contra-indicated in the treatment of PsA and psoriasis. Methods: A systematic search of MEDLINE, EMBASE and the Cochrane Library databases was performed in November 2019 to identify articles on any SGC use compared with no use in the PsA and psoriasis population. Topical glucocorticoid treatment was excluded. Our two primary outcomes focused on the prescribing characteristics and the occurrence of any type of flare. Results: Our search yielded 4922 articles, and of these 21 full-text articles were eligible for inclusion. There were 11 retro- and prospective cohorts involving a total of 4, 171, 307 patients. Of these, 6727 (37.82%) of the patients with PsA and 1 460 793 (35.17%) of the patients with psoriasis were treated with any type of SGC. Ten observational/interventional studies did not report an increased risk or occurrence of psoriatic flares related to SGC use. Conclusion: Our results indicate that SGCs are frequently prescribed for PsA and psoriasis patients. The occurrence of psoriatic flares appears to be low upon SGC exposure. In patients with a clear indication for SGCs, e.g. in need of rapid anti-inflammatory therapy or bridging of therapies, the use of SGCs should be considered in view of the low risk of skin flaring. It remains of importance to weigh risks for short- and long-term SGC-related side effects in clinical decision making.